With 50%–70% radiochemical yield and >95% radiochemical purity, 191Pt-MYCN-PIP achieved ∼10-fold higher uptake and DNA-binding in MYCN-amplified vs. non-amplified neuroblastoma cells, and reduced MYCN expression in vitro (35). The gene discussed is MYCN; the disease is neuroblastoma.